Vemurafenib for BRAFV600E-positive metastatic papillary thyroid cancer – Authors' response

Marcia S. Brose; Nathan Singh

doi:10.1016/S1470-2045(16)30520-4

Vemurafenib for BRAF^V600E-positive metastatic papillary thyroid cancer – Authors' response

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	e469
Journal	The Lancet Oncology
Volume	17
Issue number	11
DOIs	https://doi.org/10.1016/S1470-2045(16)30520-4
State	Published - Nov 1 2016

Access to Document

10.1016/S1470-2045(16)30520-4

Cite this

@article{23b5a5437d4042479ba67cc392632554,

title = "Vemurafenib for BRAFV600E-positive metastatic papillary thyroid cancer – Authors' response",

author = "Brose, {Marcia S.} and Nathan Singh",

note = "Funding Information: MSB reports research grants, consultant fees, and honoraria from Bayer Healthcare Pharmaceuticals, Exelixis, and Eisai; consultant fees from Onyx Pharmaceuticals; and research grants from Genentech and Novartis; all outside the submitted work. NS declares no competing interests.",

year = "2016",

month = nov,

day = "1",

doi = "10.1016/S1470-2045(16)30520-4",

language = "English",

volume = "17",

pages = "e469",

journal = "The Lancet Oncology",

issn = "1470-2045",

number = "11",

}

TY - JOUR

T1 - Vemurafenib for BRAFV600E-positive metastatic papillary thyroid cancer – Authors' response

AU - Brose, Marcia S.

AU - Singh, Nathan

N1 - Funding Information: MSB reports research grants, consultant fees, and honoraria from Bayer Healthcare Pharmaceuticals, Exelixis, and Eisai; consultant fees from Onyx Pharmaceuticals; and research grants from Genentech and Novartis; all outside the submitted work. NS declares no competing interests.

PY - 2016/11/1

Y1 - 2016/11/1

UR - http://www.scopus.com/inward/record.url?scp=84995685144&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(16)30520-4

DO - 10.1016/S1470-2045(16)30520-4

M3 - Letter

C2 - 27819236

AN - SCOPUS:84995685144

SN - 1470-2045

VL - 17

SP - e469

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 11

ER -

Vemurafenib for BRAFV600E-positive metastatic papillary thyroid cancer – Authors' response

Access to Document

Other files and links

Cite this

Vemurafenib for BRAF^V600E-positive metastatic papillary thyroid cancer – Authors' response